Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia.
about
Refractory schizophrenia and atypical antipsychoticsChlorpromazine versus atypical antipsychotic drugs for schizophreniaOlanzapine versus other atypical antipsychotics for schizophreniaOlanzapine for schizophreniaRisperidone versus olanzapine for schizophreniaOlanzapine versus other atypical antipsychotics for schizophreniaRisperidone versus olanzapine for schizophreniaCurrent perspectives in the treatment of resistant schizophreniaOlanzapine for schizophrenia.A composite approach that includes dropout rates when analyzing efficacy data in clinical trials of antipsychotic medicationsSwitching antipsychotic therapies.Treatment of negative and cognitive symptoms.Should the treatment of schizophrenia include old antipsychotic drugs?Treatment-refractory schizophrenia.Xerostomia and the geriatric patient.Diagnosing, managing, and preventing salivary gland disorders.Effects of olanzapine and ziprasidone on glucose tolerance in healthy volunteers.Levomepromazine versus chlorpromazine in treatment-resistant schizophrenia: a double-blind randomized trial.Developments in the pharmacological treatment of schizophrenia.Information for physicians and pharmacists about drugs that might cause dry mouth: a study of monographs and published literature.Treatment of the special patient with schizophrenia.Treatments for chronic psychosis.The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychoticsAtypical Antipsychotic Use in the Treatment of Psychosis in Primary CareRisk:benefit assessment of old medicines.The impact of European regulatory policies on psychotropic drug prescribing patterns.Olanzapine: a critical review of recent literature.Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or cul-de-sac?Are second generation antipsychotics a distinct class?Adding or switching antipsychotic medications in treatment-refractory schizophrenia.Dropout rates in randomized clinical trials of antipsychotics: a meta-analysis comparing first- and second-generation drugs and an examination of the role of trial design featuresCiprofloxacin and Clozapine: A Potentially Fatal but Underappreciated Interaction.Efficacy of risperidone, olanzapine and clozapine in the treatment of therapy resistant schizophrenia.Atypical antipsychotics: revolutionary or incremental advance?Pharmacologic treatment of schizophrenia: what the future holds.Are older antipsychotic drugs obsolete?Lethal catatonia responding to high-dose olanzapine therapy.Olanzapine in Chinese treatment-resistant patients with schizophrenia: an open-label, prospective trial.Clozapine but not haloperidol Re-establishes normal task-activated rCBF patterns in schizophrenia within the anterior cingulate cortex.More powerful two-sample tests for differences in repeated measures of adverse effects in psychiatric trials when only some patients may be at risk.
P2860
Q22241831-E74EF764-32D0-4DF7-AB73-C8C96647E1BFQ24185922-E1021489-A060-4A84-98A2-72E8FAA87E6FQ24236545-8DADB00A-4F28-4AA0-A0C1-95378AE57A42Q24244031-2B79C1BC-CFA9-4372-93B9-613C665D64C5Q24244248-7A81A41A-D4A6-4DB0-9323-4E172502FB44Q24244590-E0D368D1-6B8E-4F17-86E2-4C3A4941D9CFQ24246232-67EB1C80-432A-41CA-AA35-1CCD43CFCF11Q24650594-92D85F07-4626-4011-B107-3D5FE6800425Q30868034-9480A4ED-001D-4E40-B2A2-F69C2F6157B5Q31131634-2E5CBBC7-E739-4858-B088-465A85572000Q33838916-A73B3FE6-8D85-478B-B21E-FAD78163D760Q34108164-94C317F0-2188-4926-813F-519BEFFE0E0AQ34108518-3A7C867B-9959-4459-8927-AC5A9468BEADQ34370955-C19AC7E1-EDF4-4BA3-899A-93645FD77C4FQ34593888-ACE4EE40-4FE7-4C7E-97D4-9D2F5E6372F9Q34625299-991A3275-3968-40B9-876C-689C10BFBE03Q34665858-8428DDDC-467F-40BC-A9EC-65A8DA274C67Q34716524-F8ED83AA-B42F-4BB6-94BC-313EB0CCAE86Q34974846-A7BA4B72-C82A-4D90-9419-F61F9A42337CQ35057288-6FC5556E-69BC-4574-8857-22E9FD618CDBQ35236370-E1624751-0259-4DCC-8898-976A086B22A4Q35236418-B195810E-AC8F-473A-97D9-C536D4E266E9Q35370032-63D3C923-26F7-4D9A-8A23-C45A17F62DD4Q35665593-5247091C-143A-424C-AC61-03277A722B3AQ35826523-72FD09F3-37D8-4308-88D9-0B4F47FE3EB1Q36272515-95FCDF3B-E981-4703-8693-D5AF464F317DQ36273449-A892458F-B59B-4BA0-8E9C-1DE19B737D5BQ36715888-5A117F53-96E3-4799-BF52-1986A79C1FBFQ36784527-AFCCD5B7-82A4-4CBC-B5E1-BE9213D9CE43Q36905070-AFEA5572-3673-4F00-83DE-67A2836D3EE0Q37227479-75B4392E-9098-4BC5-B0EE-1FC246ABFCE1Q37410806-A7CC300C-2DEC-4E59-B68B-55C78C2E482EQ38774207-77D83B29-FB48-4FE8-828E-0931A03E6399Q39412178-5EDA6267-8827-43EB-8291-20FE19B9837FQ40489435-FA1E0796-1746-47C3-B921-ABF430BFEB4BQ42412715-F634DF7C-FBCC-4431-A7CE-681288D8B7FFQ43841271-FF01D5D7-EE6C-4246-8726-3BF02CCDB092Q44570187-2D5BE4AA-7D12-463D-8F1F-67C961711F99Q44603419-A2DC85B7-8AB8-40AA-AD2E-E4F7A747F801Q45130734-C18B7FF7-2178-4F46-BECE-0251795957D5
P2860
Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia.
@en
Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia.
@nl
type
label
Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia.
@en
Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia.
@nl
prefLabel
Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia.
@en
Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia.
@nl
P2093
P356
P1476
Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia.
@en
P2093
C A Tamminga
C Gounaris
C Richardson
J J Bartko
R R Conley
P304
P356
10.1176/AJP.155.7.914
P407
P577
1998-07-01T00:00:00Z